The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

Medicare Advantage (MA) insurers Alignment Healthcare and Clover Health both reported increased membership growth ahead of ...

The current head of the Center for Medicare has advice for her successor: "Engaging everyone in the ecosystem" is the ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

After several years in the doldrums, pharmaceutical companies and biotechs expect an uptick in dealmaking in 2025, with some ...

AbbVie's CEO hinted his company may be less willing to invest in psychiatry, while Lilly explained what it got wrong forecasting GLP-1 drug demand.

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Winning with a top-flight investment framework. Our research team assigns Neutral ratings to strategies they’re not confident will outperform a relevant index, or most peers, over a market cycle ...

Rowe Price before joining J.P. Morgan in 2003. His background suits ... as solid picks in communication services and healthcare drove the strategy’s 34.1% gain, beating the index’s 32.2% ...

Healthcare & Pharmaceuticalscategory Novartis wins temporary pause to Entresto generic launch in US 2:11 AM UTC Legalcategory Gilead Sciences, US government settle patent case over HIV prevention ...